JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267089

Human IFI27 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

IFI27 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 146 bp deletion in exon 4. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human IFI27 knockout A549 cell line (AB267089)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFI27 knockout A549 cell line (AB267089)

Homozygous : 146 bp deletion in exon4

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 146 bp deletion in exon 4

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267089-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267089-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267089 Human IFI27 knockout A549 cell line", "number":"AB267089-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267089-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267089-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267089 Human IFI27 knockout A549 cell line", "number":"AB267089-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267089-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267089 Human IFI27 knockout A549 cell line", "number":"AB267089-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267089-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267089 Human IFI27 knockout A549 cell line", "number":"AB267089-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IFI27
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

IFI27 also known as Interferon alpha-inducible protein 27 is a small protein with a molecular mass of around 12 kilodaltons. This protein is expressed predominantly in response to type I interferons and some other stimuli. It mainly appears in tissues like the skin and liver which are involved in immune responses. IFI27 localizes to the mitochondria suggesting its role in regulating cellular apoptosis.
Biological function summary

IFI27 plays a significant role in mediating apoptosis the programmed cell death essential for normal cellular turnover and homeostasis. Although it does not typically form part of a larger protein complex its induction by interferons implicates it in antiviral defense mechanisms. Its expression can lead to changes in mitochondrial membrane potential ultimately affecting cell survival.

Pathways

IFI27 participates in important pathways related to immunity and apoptosis. Particularly it engages in the interferon signaling pathway influencing the cellular defense against viral infections. It interacts with other proteins like STAT1 and STAT2 which are key transcription factors in the interferon signaling cascade modulating downstream antiviral responses.

IFI27 has associations with chronic liver diseases and certain autoimmune conditions such as systemic lupus erythematosus (SLE). Its elevated expression often indicates an active immune response or cellular stress. IFI27's expression relates to IFI6 another interferon-inducible protein both of which are implicated in the cellular responses observed in these conditions. Understanding IFI27's role may help in developing therapeutic strategies for targeting immune-related disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com